Breaking News

CaroGen, BioCentriq Enter Clinical Manufacturing Pact

BioCentriq to provide clinical manufacturing to support Phase 1 clinical trials of CaroGen's lead immunotherapy candidate, CARG-201.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CaroGen Corp. has selected BioCentriq for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201 which has been designed to generate multiple hepatitis B virus (HBV) antigens and to stimulate broad immune responses.   BioCentriq is a NJ-based full-service CDMO and offers process development and clinical manufacturing services for the cell and gene therapy industry along with a workforce development arm designed to help the industry adopt best pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters